FDA inspection
Dermazone Solutions, Inc.: FDA inspection ending Dec 6, 2022
FDA inspection 1192111 · Voluntary Action Indicated (VAI) · Saint Petersburg, FL
Key facts
| Inspection ID | 1192111 |
|---|---|
| Firm | Dermazone Solutions, Inc. |
| FEI number | 1000113908 |
| Address | 2440 30th Ave N |
| City | Saint Petersburg |
| State | FL |
| ZIP | 33713-2920 |
| Fiscal year | 2023 |
| Inspection end date | Dec 6, 2022 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data